Ablexis Reports 33 AlivaMab(R) Mouse-Derived Human Antibodies Now in Clinical Development

Further Validating AlivaMab Mouse Transgenic Platform

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Ablexis, LLC, a biopharmaceutical company advancing human antibody drug discovery through its AlivaMab Mouse platform, announced that licensees have advanced at least 33 AlivaMab Mouse-derived antibody drug candidates into clinical development, with at least two of these drug candidates having progressed into pivotal phase 3 clinical trials.

Why it matters

The AlivaMab Mouse platform is a patented, next-generation suite of transgenic mice that serves as a foundational platform for human antibody drug discovery and development. The fact that 33 drug candidates derived from this platform have now entered clinical development, with two progressing to pivotal phase 3 trials, is a significant validation of the platform's capabilities and potential to advance new therapeutic antibodies.

The details

Ablexis CEO Larry Green, Ph.D. stated that the AlivaMab Mouse is engineered for high efficiency in human antibody drug discovery and development, addressing the risks and limitations of other technologies. The 33 clinical candidates reported reflect the productivity of earlier AlivaMab Mouse generations, and the company's continuous improvements mean the clinical pipeline built on today's AlivaMab Mouse technology will be even more robust.

  • Ablexis announced the 33 clinical candidates on March 4, 2026.
  • At least two of the 33 drug candidates have progressed into pivotal phase 3 clinical trials.

The players

Ablexis, LLC

A biopharmaceutical company advancing human antibody drug discovery through its AlivaMab Mouse platform.

Larry Green, Ph.D.

Chief Executive Officer of Ablexis.

AlivaMab Mouse

A patented, next-generation suite of transgenic mice serving as a foundational platform for human antibody drug discovery and development.

Got photos? Submit your photos here. ›

What they’re saying

“The patented AlivaMab Mouse is engineered for high efficiency in human antibody drug discovery and development, addressing the risks and limitations inherent to display technologies and other transgenic platforms that make 'full human' and 'reverse chimeric' antibodies.”

— Larry Green, Ph.D., Chief Executive Officer of Ablexis

The takeaway

The rapid advancement of 33 AlivaMab Mouse-derived antibody drug candidates into clinical development, with two progressing to pivotal phase 3 trials, demonstrates the significant potential of Ablexis' transgenic mouse platform to drive the discovery and development of new human therapeutic antibodies.